Abstract
Despite no clear explanation of the mechanism underlying chronic daily headache, sensitization of central nociceptive neurons is one possibility. Either prolonged activation of peripheral nociceptors or any factors that can alter the endogenous pain control system can trigger this process. A decrease in platelet serotonin has been observed in patients with chronic tension-type headache as well as migraine patients with medication-induced headache. It was also shown that chronic analgesic exposure led to changes in the serotonin content and the density of the 5-HT2A receptor in the cerebral cortex. The plasticity of the serotonin-dependent pain control system may facilitate the process of sensitization and results in the development of chronic daily headache.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Silberstein SD, Lipton R, Solomon S, Mathew N: Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994, 34:1–7.
Srikiatkhachorn A, Phanthumchinda K: Prevalence and clinical features of chronic daily headache in a headache clinic. Headache 1997, 37:277–280.
Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual followup. Neurology 2000, 54:314–319.
Spierings Ranke AH, Schroevers M, Honkoop PC: Chornic daily headache: a time perspective. Headache 2000, 40:306–310.
Sakai F, Ebihara S, Akiyama M, Horikawa M: Pericranial muscle hardness in tension-type headache. A non-invasive measurement method and its clinical application. Brain 1995, 118:523–531.
Ashina M, Bendtsen L, Jensen R, et al.: Muscle hardness in patients with chronic tension-type headache: relation to actual headache state. Pain 1999, 79:201–205.
Silberstein SD, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445–450.
Klapper JA, Klapper A: Use of botulinum toxin in chronic daily headaches associated with migraine. Headache Q 1999, 10:141–143.
Smuts JA, Baker MK, Smuts HM, et al.: Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999, 6:S99-S102.
Evers S, Voss H, Bauer B, et al.: Peripheral autonomic potentials in primary headache and drug-induced headache. Cephalalgia 1998, 18:216–221.
Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8:1–10. Summarized the plasticity of the nociceptive system and changes in the signal transduction cascades involved in the pathophysiologic process underlying the development of pathologic pain. Details of the biochemical mechanism were described.
Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurones. J Neurophysiol 1998, 79:964–982.
Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for sequential recruitment of spinal and supraspinal nociceptive neurones in migraine. Brain 2000, 123:1703–1709. Described the temporal pattern of cutaneous allodynia developed during the migrainous attack. Based on this finding, the authors suggest that higher-order neurons are sequential sensitized, and thus emphasize the role of central sensitization in the development of headache and cutaneous allodynia.
Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614–624.
Malick A, Burstein R: Peripheral and central sensitization during migraine. Funct Neurol 2000, 15(suppl 3):28–35.
Bendtsen L: Central sensitization in tension-type headache—possible pathophysiological mechanisms. Cephalalgia 2000, 20:486–508. Extensively reviewed the evidence in support of the role of central sensitization in the development of chronic tension-type headache. The possible hypothesis was proposed.
Staud R, Vierck CJ, Cannon RL, et al.: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165–175.
Kleinbohl D, Holzl R, Moltner A, et al.: Psychophysical measures of sensitization to tonic heat discriminate chronic pain patients. Pain 1999, 81:35–43.
Fusco BM, Colantoni O, Giacovazzo M: Alteration of central excitation circuits in chronic headache and analgesic misuse. Headache 1997, 37:486–491.
Schnider P, Maly J, Grunberger J, et al.: Improvement of decreased critical flicker frequency (CFF) in headache patients with drug abuse after successful withdrawal. Headache 1995, 35:269–272.
Schnider P, Maly J, Mraz M, et al.: MMPI and critical flicker frequency (CFF) analysis in headache patients with and without drug abuse. Headache 1995, 35:17–20.
Evers S, Schmidt F, Bauer B, et al.: The impact of ergotamineinduced headache and ergotamine withdrawal on information processing. Psychopharmacology 1999, 142:61–67.
Roon KI, Bakker D, van Poelgeest MI, et al.: The influence of ergotamine abuse on psychological and cognitive functioning. Cephalalgia 2000, 20:462–469.
Schoenen J, Maertens de Noordhout A, Timsit-Berthier M, Timsit M: Contingent negative variation (CNV) as a diagnostic and physiologic tool in headache patients. In Migraine: Clinical and Research Advances. Edited by Clifford RF. Basel: Kager; 1985:17–25.
Siniatchkin M, Gerber WD, Kropp P, Vein A: Contingent negative variation in patients with chronic daily headache. Cephalalgia 1998, 18:565–569.
Linderoth B, Gazelius B, Franck J, Brodin E: Dorsal column stimulation induces release of serotonin and substance P in the cat dorsal horn. Neurosurgery 1992, 31:289–297.
Pini LA, Sandrini M, Vitale G: The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol 1996, 308:31–40.
Björkman R: Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand 1995, 39(suppl 103):1–44.
Nicolodi M, Volpe AR, Sicuteri F: Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartatemediated neuronal plasticity: their common clues. Cephalalgia 1998, 18(suppl 21):41–44.
Srikiatkhachorn A, Anthony M: Platelet serotonin in patients with analgesic induced headache. Cephalalgia 1996, 16:423–426.
Srikiatkhachorn A, Maneesri S, Govitrapong P, Kasantikul V: Derangement of serotonin system in migraine patients with analgesics abuse headache: clues from platelets. Headache 1998, 38:43–49.
Sarchielli P, Alberti A, Russo S, et al.: Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 1999, 19:810–816. Using the platelet as a neuronal model, the authors demonstrated the occurrence of an activation of cGMP-Ca2+ mediated events in CDH patients with analgesic abuse. They also suggested that the physiologic compensatory mechanism, which intervenes in overcoming the increase in cytosolic Ca2+ levels, is not efficient in these patients due to the depletion of serotonin.
Hering R, Glover V, Pattichis K, et al.: 5HT in migraine patients with medication-induced headache. Cephalalgia 1993, 13:410–412.
Srikiatkhachorn A, Anthony M: Serotonin receptor adaptation in patients with analgesic induced headache. Cephalalgia 1996, 16:419–422.
Srikiatkhachorn A, Puangniyom S, Govitrapong P: Plasticity of 5-HT2A serotonin receptor in patients with analgesicinduced transformed migraine. Headache 1998, 38:534–539.
Hering R, Gardiner I, Catarci T, et al.: Cellular adaptation in migraineurs with chronic daily headache. Cephalalgia 1993, 13:261–266.
Srikiatkhachorn A, Tarasub N, Govitrapong P: Acetaminopheninduced antinociception via central 5-HT2A receptors. Neurochem Int 1999, 34:491–498.
Srikiatkhachorn A, Tarasub N, Govitrapong P: Effect of chronic analgesic exposure on the central serotonin system. A possible mechanism of analgesic abuse headache. Headache 2000, 40:343–350. Described the plasticity of the central serotonergic system after chronic paracetamol administration. The authors showed that the degree of 5-HT2A receptor downregulation and 5-HT transporter upregulation became minimized after chronic analgesic exposure. The relationship between these biochemical changes and the development of CDH was discussed.
Ostrowski S, Rao ML, Redei J, Andres AH: Concurrence of cortex and platelet serotonin 2 receptor binding characteristics in the individual and the putative regulation by serotonin. J Neural Transm Gen Sect 1993, 93:27–35.
Pini LA, Vitale G, Sandrini M: Serotonin and opiate involvement in the antinociceptive effect of acetylsalicylic acid. Pharmacology 1997, 54:84–91.
Srikiatkhachorn A, Anuntasethakul T, Maneesri S, et al.: Hyposerotonin-induced nitric oxide supersensitivity in the cerebral microcirculation. Headache 2000, 40:267–275.
Eide PK, Hole K: Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res 1991, 550:225–230.
Alhaider AA: Antinociceptive effects of ketanserin in mice: involvement of supraspinal 5-HT2 receptors in nociceptive transmission. Brain Res 1991, 543:335–340.
Eide PK: Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000, 4:5–15.
Nicolodi M, Del Bianco PL, Sicuteri F: Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse. Int J Clin Pharmacol Res 1997, 17:97–100.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Srikiatkhachorn, A. Pathophysiology of chronic daily headache. Current Science Inc 5, 537–544 (2001). https://doi.org/10.1007/s11916-001-0071-5
Issue Date:
DOI: https://doi.org/10.1007/s11916-001-0071-5